Case Report
Radiation Therapy and Sorafenib: Clinical Data and Rationale for the Combination in Metastatic Renal Cell Carcinoma

https://doi.org/10.3816/CGC.2007.n.007Get rights and content

Abstract

Sorafenib, an inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor and Raf/mitogen-activated protein kinase, increases progression-free survival in metastatic renal cell carcinoma (RCC) compared with placebo. The efficacy and toxicity of combined sorafenib and radiation therapy (RT) in the treatment of RCC are unknown. This is a retrospective report of 3 consecutive patients with metastatic or locally recurrent RCC treated with palliative RT while undergoing sorafenib therapy. All 3 patients experienced disease progression on sorafenib and remained on the drug without dose reduction during the RT plus sorafenib regimen. They were followed for toxicity and response by clinical history, physical examination, and contrast-enhanced computed tomography scans. Soon after completion of palliative RT, all 3 patients experienced complete pain relief without the need for narcotic pain medication. Posttreatment imaging revealed partial response with > 50% regression of tumor in all patients. None reported significant acute or late side effects at follow-up of 3, 6, and 8 months after RT and sorafenib. In the 3 patients with recurrent or metastatic RCC in this report, the combination of RT and sorafenib was well tolerated and resulted in excellent clinical and radiologic responses. This combination is promising and requires further study.

References (6)

There are more references available in the full text version of this article.

Cited by (32)

  • The role of macrophage phenotype in regulating the response to radiation therapy

    2018, Translational Research
    Citation Excerpt :

    In a murine model of pancreatic cancer, sunitinib sensitized pancreatic tumors, making them more susceptible to RT.160 In a phase 2 trial of patients with localized high-risk prostate cancer, prolonged disease control was observed with the combined application of sunitinib, chemotherapy, and RT.161 Pathologic analysis of the tissue suggested that the combination of RT, chemotherapy, and a similar tyrosine kinase inhibitor, sorafenib, can reverse TAMs to an antitumor phenotype.162 Similar enhanced efficacy was seen in metastatic renal cell carcinoma162 and unresectable hepatocellular carcinoma.163 In summary, although these agents all undoubtedly have effects outside of their impact on myeloid-macrophage cells, some of their bioactivity is likely attributable to their ability to influence the functional phenotype of macrophages.

View all citing articles on Scopus

Electronic forwarding or copying is a violation of US and International Copyright Laws.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1558-7673, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

View full text